Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb 22;6(4):1232-1242.
doi: 10.1182/bloodadvances.2021005872.

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Gareth P Gregory  1 , Shaji Kumar  2 , Ding Wang  3 , Daruka Mahadevan  4 , Patricia Walker  5 , Nina Wagner-Johnston  6 , Carolina Escobar  7 , Rajat Bannerji  8 , Divaya Bhutani  9 , Julie Chang  10 , Francisco J Hernandez-Ilizaliturri  11 , Andreas Klein  12 , John M Pagel  13 , Witold Rybka  14 , Andrew J Yee  15 , Anne Mohrbacher  16 , Mo Huang  17 , Mohammed Farooqui  17 , Patricia Marinello  17 , Hang Quach  18
Affiliations
Clinical Trial

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Gareth P Gregory et al. Blood Adv. .

Abstract

Preclinical data demonstrated that combining an anti-programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patients received pembrolizumab 200 mg every 3 weeks plus dinaciclib 7 mg/m2 on day 1 and 10 mg/m2 on day 8 of cycle 1 and 14 mg/m2 on days 1 and 8 of cycles 2 and later. Primary endpoint was safety, and a key secondary endpoint was objective response rate (ORR). Seventy-two patients were enrolled and received ≥1 dose of study treatment (CLL, n = 17; DLBCL, n = 38; MM, n = 17). Pembrolizumab plus dinaciclib was generally well tolerated and produced no unexpected toxicities. The ORRs were 29.4% (5/17, rrCLL), 21.1% (8/38, rrDLBCL), and 0% (0/17, rrMM), respectively. At data cutoff, all 72 patients had discontinued treatment, 38 (52.8%) because of progressive disease. These findings demonstrate activity with combination pembrolizumab plus dinaciclib and suggest that a careful and comprehensive approach to explore anti-PD-1 and CDK9 inhibitor combinations is warranted. This trial was registered at www.clinicaltrials.gov as NCT02684617.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Time on study and response duration* per investigator assessment. Patients with rrCLL (A), rrDLBCL (B), and rrMM (C). CR, complete response; PR, partial response. *Tumor response as assessed by investigator review according to International Workshop on CLL guidelines (2008) for the rrCLL cohort, revised International Working Group response criteria for malignant lymphoma (2007) for the rrDLBCL cohort, and International Myeloma Working Group Uniform Response Criteria (2006) for the rrMM cohort.
Figure 2.
Figure 2.
Kaplan-Meier estimates of PFS. Patients with rrCLL (A), rrDLBCL (B), and rrMM (C).
Figure 3.
Figure 3.
Kaplan-Meier estimates of overall survival. Patients with relapsed or refractory rrCLL (A), rrDLBCL (B), and rrMM (C).
See this image and copyright information in PMC

References

    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Version 1.2021. Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma. Vol. 2020. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2020.
    1. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74. - PMC - PubMed
    1. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013;22(6):723-738. - PMC - PubMed
    1. Li L, Pongtornpipat P, Tiutan T, et al. . Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015;29(8):1702-1712. - PMC - PubMed
    1. Gregory GP, Hogg SJ, Kats LM, et al. . CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia. 2015;29(6):1437-1441. - PMC - PubMed

Publication types

MeSH terms

Associated data